← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,276	+302	+10%	$458B
2	2 Pfizer PFE $168B	2,940	+12	+0.4%	$112B
3	3 Amgen AMGN $235B	2,717	+215	+9%	$119B
4	4 Becton Dickinson BDX $52.8B	1,593	+40	+3%	$61.9B
5	5 Novo Nordisk NVO $173B	1,512	+206	+16%	$32.2B
6	6 McKesson MCK $116B	1,483	+136	+10%	$52.4B
7	7 Regeneron Pharmaceuticals REGN $82B	1,273	+96	+8%	$80.8B
8	8 AstraZeneca AZN $259B	1,131	+57	+5%	$33.4B
9	9 Conagra Brands CAG $6.77B	853	+46	+6%	$11.5B
10	10 West Pharmaceutical WST $27B	783	+26	+3%	$24.3B
11	11 Lamb Weston LW $7.47B	769	+18	+2%	$13.9B
12	12 ResMed RMD $34.1B	688	+30	+5%	$14B
13	13 DaVita DVA $12.1B	536	+33	+7%	$8.3B
14	14 Teva Pharmaceutical Industries Limited TEVA $47.9B	447	+12	+3%	$6.07B
15	15 DELISTED CATALENT, INC. CTLT	424	-10	-2%	$8.9B
16	16 DELISTED WK Kellogg Co KLG	424	+408	+2,550%	$883M
17	17 BellRing Brands BRBR $1.05B	383	+54	+16%	$6.88B
18	18 Embecta EMBC $365M	374	+1	+0.3%	$1.05B
19	19 Inspire Medical Systems INSP $2.03B	343	-21	-6%	$6.32B
20	20 Amphastar Pharmaceuticals AMPH $1.12B	276	+21	+8%	$2.16B
21	21 Accendra Health ACH $20.1M	227	+17	+8%	$1.5B
22	22 Madrigal Pharmaceuticals MDGL $10.6B	226	+21	+10%	$4.58B
23	23 Dr. Reddy's Laboratories RDY $10.7B	224	+12	+6%	$1.64B
24	24 Biohaven BHVN $1.73B	218	+31	+17%	$3.07B
25	25 Opko Health OPK $1.2B	218	-7	-3%	$257M